{
    "medicine_id": "b8347a3924e2d3a1123c73d4f7e3aae8279b60b2",
    "platform_id": "DB12499",
    "metadata": {
        "name": "Poteligeo 4 mg 1mL Injection",
        "composition": "4 mg 1mL Clascoterone",
        "clinical_particulars": {
            "therapeutic_indications": "Clascoterone is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older L15626",
            "contraindications": {
                "disease": "There is no information available on the toxicity profile of clascoterone such as LD sub 50 sub and overdose in humans",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Clascoterone exerts anti androgenic effects by working as an antagonist at androgen receptors ARs expressed throughout the skin including sebaceous glands sebocytes and dermal papilla cells A218761 Clascoterone blocks the effects of testosterone and dihydrotestosterone DHT which are androgens that bind to the ARs and contribute to the development of androgen dependent conditions such as acne and alopecia A218761 _In vitro_ the antiandrogenic effects of clascoterone in human primary sebocytes occurred in a dose dependent manner A218771 Clascoterone mediates selective topical activity by mainly targeting androgen receptors at the site of application It has limited systemic effects A218761 In clinical trials HPA axis suppression was observed as a 30 minute post stimulation serum cortisol level of 18 mcg dL in 5 of adult subjects and 9 of adolescent subjects with acne vulgaris following two weeks of topical treatment of clascoterone HPA axis function returned to normal following the discontinuation of drug treatment L15626",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}